Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
Boyle
Brain A
BA
ViralEd LLC, Stockton, New Jersey, USA.
Cohen
Calvin J
CJ
DeJesus
Edwin
E
Elion
Richard
R
Frank
Ian
I
Moyle
Graeme J
GJ
Sax
Paul E
PE
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000069446:Atazanavir Sulfate; D002318:Cardiovascular Diseases / Q000139:chemically induced; D015224:Dideoxynucleosides / Q000009:adverse effects; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D009842:Oligopeptides / Q000493:pharmacokinetics; D011725:Pyridines / Q000493:pharmacokinetics; D011760:Pyrrolidinones / Q000493:pharmacokinetics; D000068898:Raltegravir Potassium; D000099227:Abacavir
D019380:Anti-HIV Agents; D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides; D007376:Interleukin-2; D009842:Oligopeptides; D011725:Pyridines; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000099227:Abacavir